Characterizing heterogeneity in the progression of Alzheimer's disease using longitudinal clinical and neuroimaging biomarkers
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Introduction: Models characterizing intermediate disease stages of Alzheimer's disease (AD) are needed to inform clinical care and prognosis. Current models, however, use only a small subset of available biomarkers, capturing only coarse changes along the complete spectrum of disease progression. We propose the use of machine learning techniques and clinical, biochemical, and neuroimaging biomarkers to characterize progression to AD. Methods: We used a large multimodal longitudinal data set of biomarkers and demographic and genotype information from 1624 participants from the Alzheimer's Disease Neuroimaging Initiative. Using hidden Markov models, we characterized intermediate disease stages. We validated inferred disease trajectories by comparing time to first clinical AD diagnosis. We trained an L2‐regularized logistic regression model to predict disease trajectory and evaluated its discriminative performance on a test set. Results: We identified 12 distinct disease states. Progression to AD occurred most often through one of two possible paths through these states. Paths differed in terms of rate of disease progression (by 5.44 years on average), amyloid and total‐tau (t‐tau) burden (by 10% and 69%, respectively), and hippocampal neurodegeneration (P < .001). On the test set, the predictive model achieved an area under the receiver operating characteristic curve of 0.85. Discussion: Progression to AD, in terms of biomarker trajectories, can be predicted based on participant‐specific factors. Such disease staging tools could help in targeting high‐risk patients for therapeutic intervention trials. As longitudinal data with richer features are collected, such models will help increase our understanding of the factors that drive the different trajectories of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cognitive reserve in ageing and Alzheimer's disease
Stern, Y. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70191-6 · Cited by 3,557 · cited 1×
“This protective effect of higher education has previously been referred to as higher cognitive reserve [42,43].”
BackgroundBiomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
Murray, M. E., Graff-Radford, N. R., Ross, O. A., Petersen, R. C., Duara, R., & Dickson, D. W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70156-9 · Cited by 972 · cited 1×
“The concept of heterogeneity in AD, that is, variations in its clinical presentation and biomarker trajectories, has been investigated previously, and several potential subtypes have been identi-fied [35–38].”
BackgroundStrategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626
Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30028-0 · Cited by 602
Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome
Lam, B., Masellis, M., Freedman, M., Stuss, D. T., & Black, S. E. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt155 · Cited by 386 · cited 2×
“Patients with AD progress through the disease at different rates (i.e., time to clinical diagnosis of AD) and with different pathophysiological responses (e.g., rate and extent of neurodegeneration) [4].”
BackgroundJack, C. R., Wiste, H. J., Weigand, S. D., Rocca, W. A., Knopman, D. S., Mielke, M. M., Lowe, V. J., Senjem, M. L., Gunter, J. L., Preboske, G. M., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70194-2 · Cited by 358
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Knopman, D. S., Lowe, V., Vemuri, P., Mielke, M. M., Roberts, R. O., Machulda, M. M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30077-7 · Cited by 333
A data-driven model of biomarker changes in sporadic Alzheimer’s disease
Young, A. L., Oxtoby, N. P., Daga, P., Cash, D. M., Fox, N. C., Ourselin, S., Schott, J. M., & Alexander, D. C. (2014) · Brain · doi:10.1093/brain/awu176 · Cited by 308
Preclinical Alzheimer disease—the challenges ahead
Sperling, R. A., Karlawish, J., & Johnson, K. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.241 · Cited by 291 · cited 1×
“Models of disease progression could be used to assess and predict patients’ intermediate disease stages in clinical trials [5] and predict”
Burnham, S. C., Bourgeat, P., Doré, V., Savage, G., Brown, B., Laws, S., Maruff, P., Salvado, O., Ames, D., Martins, R. N., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30125-9 · Cited by 207
Estimating long‐term multivariate progression from short‐term data
Donohue, M. C., Jacqmin‐Gadda, H., Le Goff, M., Thomas, R. G., Raman, R., Gamst, A. C., Beckett, L. A., Jack, C. R., Weiner, M. W., Dartigues, J., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.003 · Cited by 197 · cited 1×
“Past work has relied on cutoff scores, such as Alzheimer’s Disease Assessment Scale Cognitive Test or CDR-SB, to define abnormality [26–28] and has used a small subset of biomarkers [27,29,30].”
Method
Cited by
Duara, R., & Barker, W. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01185-z · Cited by 187
“and using machine learning methods, cluster analyses, and neural network analyses [210, 211].”
MethodVeitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., DeCarli, C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12422 · Cited by 184
“23 The study, which used hidden Markov models to align participants’ trajectories and estimate disease progression, identified tested the hypothesis that the pathological tau propagated preferentially along functionally strong and spatially short connections using resting state functional MRI…”
Self-citationLi, Q., Yang, X., Xu, J., Guo, Y., He, X., Hu, H., Lyu, T., Marra, D., Miller, A., Smith, G., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12967 · Cited by 113
“The absolute SHAP value of each feature indicates its importance.”
BackgroundBeyond the average patient: how neuroimaging models can address heterogeneity in dementia
Verdi, S., Marquand, A. F., Schott, J. M., & Cole, J. H. (2021) · Brain · doi:10.1093/brain/awab165 · Cited by 106
Martí-Juan, G., Sanroma-Guell, G., & Piella, G. (2020) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2020.105348 · Cited by 85
“[130] applied hidden Markov models, using different markers, to characterize the progression of the disease into stages, and 380”
Method
Metadata
- Authors
- Goyal, D., Tjandra, D., Migrino, R. Q., Giordani, B., Syed, Z., Wiens, J., & Initiative, A. D. N.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 10
- Issue
- 1
- Pages
- 629-637
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W2886957118
- Cited by
- 37
- References
- 12
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.